No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorKafrelsheikh University
About this trial
This study aims to assess the no-reflow in patients with STEMI after intracoronary glycoprotein IIb/IIIa inhibitors after opening of track in thrombus.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years old.
Both sexes.
Patients with STEMI. ST-segment elevated myocardial infarction is defined as typical chest pain >30 minutes with ST-segment elevation of >1 mm in at least 2 consecutive leads on the electrocardiogram or new-onset left bundle brunch block.
Disqualifiers
Treatment with thrombolytic drugs in the previous 24 hours.
Known malignancy.
Thrombocytopenia.
End-stage liver disease.
Trial design
Design model
Parallel
Treatments tested in this trial
Intracoronary tirofiban
DrugPatients will receive intracoronary tirofiban (Aggrastat®) (25 mg/kg).
Saline 0.9%
DrugPatients will receive intracoronary saline 0.9% solution as a control group.
Treatment groups
60 Participants
are divided into 2 treatment groupsGroup A: Intracoronary tirofiban groupExperimental treatment 1 intervention
Group B: Control groupPlacebo comparator 1 intervention
Trial outcomes
Primary outcomes
1
Blood stream
Blood stream in coronary artery before and after treatment, including Thrombolysis in Myocardial Infarction (TIMI) flow grade in IRAs, coronary blood flow will be calculated with TIMI frame count method.
Time frame
After treatment (Up to 15 minutes)Secondary outcomes
1
Incidence of major adverse cardiac events
Incidence of major adverse cardiac events were recorded.
Time frame
After treatment (Up to 30 days)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov